-+ 0.00%
-+ 0.00%
-+ 0.00%

Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

Benzinga·09/23/2026 17:36:04
Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.